Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Profit After Tax: 2019-2024

Historic Profit After Tax for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$343.0 million.

  • Lyell Immunopharma's Profit After Tax rose 12.87% to -$38.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$325.7 million, marking a year-over-year decrease of 59.65%. This contributed to the annual value of -$343.0 million for FY2024, which is 46.18% down from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Profit After Tax is -$343.0 million, which was down 46.18% from -$234.6 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Profit After Tax peaked at -$183.1 million during FY2022, and registered a low of -$343.0 million during FY2024.
  • For the 3-year period, Lyell Immunopharma's Profit After Tax averaged around -$253.6 million, with its median value being -$234.6 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Profit After Tax crashed by 58.04% in 2020 and then climbed by 26.82% in 2022.
  • Lyell Immunopharma's Profit After Tax (Yearly) stood at -$204.5 million in 2020, then decreased by 22.37% to -$250.2 million in 2021, then climbed by 26.82% to -$183.1 million in 2022, then dropped by 28.13% to -$234.6 million in 2023, then slumped by 46.18% to -$343.0 million in 2024.